Positive allosteric modulation of the adenosine A2a receptor attenuates inflammation

Journal of Inflammation

Edward P Amento¹  Ajith A Welihinda¹ 

[1] Molecular Medicine Research Institute, 428 Oakmead Parkway, Sunnyvale 94085, CA, USA

关键词: Inhibition of TNF-α production;    Positive allosteric modulator;    Inflammation;    Allosteric enhancement;    G protein-couple receptor;    Adenosine A2a receptor;   

Others  :  1140717
DOI  :  10.1186/s12950-014-0037-0

 received in 2014-01-18, accepted in 2014-11-13,  发布年份 2014

【 摘 要 】

Background

Adenosine is produced at high levels at inflamed sites as a by-product of cellular activation and breakdown. Adenosine mediates its anti-inflammatory activity primarily through the adenosine A_2a receptor (A_2aR), a member of the G-protein coupled receptors. A_2aR agonists have demonstrated anti-inflammatory efficacy, however, their therapeutic utility is hindered by a lack of adenosine receptor subtype selectivity upon systemic exposure. We sought to harness the anti-inflammatory effects of adenosine by enhancing the responsiveness of A_2aR to endogenously produced adenosine through allosteric modulation. We have identified a family of positive allosteric modulators (PAMs) of the A_2aR. Using one member of this PAM family, AEA061, we demonstrate that A_2aRs are amenable to allosteric enhancement and such enhancement produces increased A_2aR signaling and diminished inflammation in vivo.

Methods

A_2aR activity was evaluated using a cell-based cAMP assay. Binding affinity of A_2aR was determined using [³H]CGS 21680. A_2aR-mediated G-protein activation was quantified using [³⁵S]GTP-γS. The effect of AEA061 on cytokine production was evaluated using primary monocytes and splenocytes. The anti-inflammatory effect of AEA061 was evaluated in the LPS-induced mouse model of inflammation.

Results

AEA061 had no detectable intrinsic agonist activity towards either rat or human A_2aRs. AEA061 enhanced the efficacy of adenosine to rat and human A_2aRs by 11.5 and 2.8 fold respectively. AEA061 also enhanced the maximal response by 4.2 and 2.1 fold for the rat and the human A_2aR respectively. AEA061 potentiated agonist-mediated Gα activation by 3.7 fold. Additionally, AEA061 enhanced both the affinity as well as the B_max at the human A_2aR by 1.8 and 3 fold respectively. Consistent with the anti-inflammatory role of the A_2aR, allosteric enhancement with AEA061 inhibited the production of TNF-α, MIP-1α, MIP-1β, MIP-2, IL-1α, KC and RANTES by LPS-stimulated macrophages and/or splenocytes. Moreover, AEA061 reduced circulating plasma TNF-α and MCP-1 levels and increased plasma IL-10 in endotoxemic A_2aR intact, but not in A_2aR deficient, mice.

Conclusions

AEA061 increases affinity and B_max of A_2aR to adenosine, thereby increasing adenosine potency and efficacy, which translates to enhanced A_2aR responsiveness. Since the A_2aR negatively regulates inflammation, PAMs of the receptor offer a novel means of modulating inflammatory processes.

【 授权许可】

   
2014 Welihinda and Amento;licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Sabroe I, Parker L, Dower S, Whyte M: The role of TLR activation in inflammation. J Pathol 2008, 214:126-135.
• [2]Tkaczyk C, Okayama Y, Metcalfe DD, Gilfillan AM: Fc gamma receptors on mast cells: activatory and inhibitory regulation of mediator release. Int Arch Allergy Immunol 2008, 133:305-315.
• [3]Sperlágh B, Dóda M, Baranyi M, Haskó G: Ischemic-like condition releases norepinephrine and purines from different sources in superfused rat spleen strips. J Neuroimmunol 2000, 111:45-54.
• [4]Martin C, Leone M, Viviand X, Ayem ML, Guieu R: High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit Care Med 2000, 28:3198-3202.
• [5]Sottofattori E, Anzaldi M, Ottonello L: HPLC determination of adenosine in human synovial fluid. J Pharm Biomed Anal 2001, 24:1143-1146.
• [6]Ralevic V, Burnstock G: Receptors for purines and pyrimidines. Pharmacol Rev 1998, 50:413-492.
• [7]Sitkovsky MV: Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol 2003, 65:493-501.
• [8]Haskó G, Cronstein BN: Adenosine: An endogenous regulator of innate immunity. Trends Immunol 2004, 25:33-39.
• [9]Olah ME: Identification of A2a adenosine receptor domains involved in selective coupling to Gs. Analysis of chimeric A1/A2a adenosine receptors. J Biol Chem 1997, 272:337-344.
• [10]Ohta A, Sitkovsky M: Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001, 414:916-920.
• [11]Christopoulos A, Kenakin T: G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2000, 54:323-374.
• [12]Leach K, Sexton PM, Christopoulos A: Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 2000, 28:382-389.
• [13]Nagano N: Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther 2006, 109:339-365.
• [14]Kazmierski WM, Boone L, Lawrence W, Watson C, Kenakin T: CCR5 chemokine receptors: gatekeepers of HIV-1 infection. Curr Drug Targets Infect Disord 2002, 2:265-278.
• [15]Welihinda AA, Amento EP: Functional characterization of an allosteric enhancer of the adenosine A2a receptor that inhibits pro-inflammatory cytokine production [abstract]. Arthritis Rheum 2011, 63(s10):1812.
• [16]Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Kull B, Fredholm BB, Lohse MJ: Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 1998, 357:1-9.
• [17]Gao ZG, Kim SK, Gross AS, Chen A, Blaustein JB, Jacobson KA: Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor. Mol Pharmacol 2003, 63:1021-1031.
• [18]Brown RA, Spina D, Page CP: Adenosine receptors and asthma. Br J Pharmacol 2008, 153(Suppl 1):446-456.
• [19]Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE: International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev 2011, 63:1-34.
• [20]Zhang JG, Hepburn L, Cruz G, Borman RA, Clark KL: The role of adenosine A2A and A2B receptors in the regulation of TNF-[alpha] production by human monocytes. Biochem Pharmacol 2005, 69:883-889.
• [21]Kreckler LM, Wan TC, Ge ZD, Auchampach JA: Adenosine Inhibits TNF-α Release from Mouse Peritoneal Macrophages via A2A and A2B, but not the A3 Adenosine Receptor. J Pharmacol Exp Ther 2006, 317:172-180.
• [22]Hamano R, Takahashi HK, Iwagaki H, Kanke T, Liu K, Yoshino T, Sendo T, Nishibori M, Tanaka N: Stimulation of adenosine A2A receptor inhibits LPS-induced expression of intercellular adhesion molecule 1 and production of TNF-alpha in human peripheral blood mononuclear cells. Shock 2008, 29:154-159.
• [23]Bruns RF, Lu GH: Enhancement of adenosine agonist binding by substituted 1-benzopyran-2-one. In adenosine receptors in the nervous system. 1st edition. Academic Press, London; 1989:192. (July 13, 2011)
• [24]Giorgi I, Biagi G, Bianucci AM, Borghini A, Livi O, Leonardi M, Pietra D, Calderone V, Martelli A: N6-1,3-diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: synthesis and biological evaluation as allosteric modulators of A2A adenosine receptors. Eur J Med Chem 2008, 43:1639-1647.
• [25]Milne GR, Palmer TM: Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. ScientificWorldJournal 2011, 11:320-339.
• [26]Moore CC, Martin EN, Lee GH, Obrig T, Linden J, Scheld WM: An A2A adenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models. BMC Infect Dis 2008, 8:141-150. BioMed Central Full Text
• [27]Kaufmann I, Hoelzl A, Schliephake F, Hummel T, Chouker A, Łysenko L, Peter K, Thiel M: Effects of adenosine on functions of polymorphonuclear leukocytes from patients with septic shock. Shock 2007, 27:25-31.
• [28]Kreth S, Kaufmann I, Ledderose C, Luchting B, Thiel M: Reduced ligand affinity leads to an impaired function of the adenosine A2A receptor of human granulocytes in sepsis. J Cell Mol Med 2009, 13:985-994.
• [29]Haskó G, Linden J, Cronstein B, Pacher P: Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008, 7:759-770.
• [30]Jacobson KA, Gao ZG: Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006, 5:247-264.
• [31]Cristalli G, Lambertucci C, Marucci G, Volpini R, Dal Ben D: A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists. Curr Pharm Des 2008, 14:1525-1552.
• [32]Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H: A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 2006, 45:1201-1212.
• [33]Mingote S, Pereira M, Farrar AM, McLaughlin PJ, Salamone JD: Systemic administration of the adenosine A2A agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intake. Pharmacol Biochem Behav 2008, 89:345-351.